
    
      With this study we hope to evaluate safety and feasibility of the use of Rituximab as an
      adjunct to standard therapy (plasmapheresis + steroids) for patients with thrombotic
      thrombocytopenic purpura (TTP). This includes evaluating the rate and type of treatment
      failure.
    
  